Details

NameSymbolSector
EPIGRAL LIMITEDEPIGRALSpecialty Chemicals
Open
974.4
High
999.5
Low
970.1
Close
995.8
Volume
21658
Exchange
nse
Time
16-Oct-2026

Outlook

Score:  

5.5

Rating:  

FAIR

Candlestick Pattern

Candle pattern of Epigral is  
Normal
Estimated Stoploss of Epigral is ₹  
970.1
Epigral has a  
Bullishℹ
 pattern. 
Formation of  
Normal
 candle pattern indicates the trend direction of Epigral is  
Unpredictableℹ
. 

Trend

Epigral is in  
Sideways trendℹ
. 
Price of Epigral is  
Downℹ
 by  

7.91

%. 
Target
Buy @ 

938.42

Sell @ 

1233.66

Current @ 

995.8

Volume

The trade volumes of Epigral have become  
Deficientℹ
The volume trend for Epigral is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Epigral is  

Down

 by  

75.24

% 

Valuation

The current market price of Epigral is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 3152cr and total assets worth ₹ 3152cr, the balance sheet of Epigral is:  
Balancedℹ
. 
Cashflow
Epigral has  
Maintainedℹ
 cash flow because there is  

Surplus

 of  

₹ 15cr

. It is  
Upℹ
 by  

236.36

%. 

(*Mar 2025)

50.93% i.e. ₹ 440cr earned in operatingℹ
30.21% i.e. ₹ 261cr spent in investingℹ
18.87% i.e. ₹ 163cr spent in financingℹ
0% in otherℹ
Epigral has  
Badℹ
 cash flow because there is  

Shortage

 of  

₹ 11cr

. It is  
Downℹ
 by  

10

%. 

(*Mar 2024)

49.32% i.e. ₹ 397cr earned in operatingℹ
49.81% i.e. ₹ 401cr spent in investingℹ
0.87% i.e. ₹ 7cr spent in financingℹ
0% in otherℹ
Income
The income of Epigral is  

₹ 589cr

 and  

Profit

 is :  

₹ 51cr

(*Sep 2025)

Epigral Profit is up by:  

86.05

% and Income is Down by:  

2.69

% 

(*Sep 2025)

The income of Epigral is  

₹ 614cr

 and  

Profit

 is :  

₹ 160cr

(*Jun 2025)

Epigral Profit is down by:  

16.5

% and Income is Down by:  

2.77

% 

(*Jun 2025)

The income of Epigral is  

₹ 631cr

 and  

Profit

 is :  

₹ 86cr

(*Mar 2025)

Epigral Profit is up by:  

28.75

% and Income is Up by:  

2.85

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.